Literature DB >> 1702756

Where does serum amylase come from and where does it go?

C Pieper-Bigelow1, A Strocchi, M D Levitt.   

Abstract

The serum amylase concentration reflects the balance between the rates of amylase entry into and removal from the blood. Hyperamylasemia can result either from an increased rate of entry of amylase into the circulation and/or a decreased metabolic clearance of this enzyme. The pancreas and salivary glands have amylase concentrations that are several orders of magnitude greater than that of any other normal tissue, and these two organs probably account for almost all of the serum amylase activity in normal persons. A variety of techniques are now available to distinguish pancreatic from salivary-type isoamylase. Pancreatic hyperamylasemia results from an insult to the pancreas, ranging from trivial (cannulation of the pancreatic duct) to severe (pancreatitis). In addition, loss of bowel integrity (infarction or perforation) causes pancreatic hyperamylasemia due to absorption of amylase from the intestinal lumen. Hyperamylasemia due to salivary-type isoamylase is observed in conditions involving the salivary glands. In addition, this type of hyperamylasemia occurs in conditions in which there is no clinical evidence of salivary gland disease, such as chronic alcoholism, postoperative states (particularly postcoronary bypass), lactic acidosis, anorexia nervosa or bulimia, and malignant neoplasms that secrete amylase. Hyperamylasemia can also result from decreased metabolic clearance of amylase due to renal failure or macroamylasemia (a condition in which an abnormally high-molecular-weight amylase is present in the serum). Patients with abdominal pain and a markedly elevated serum amylase (more than three times the upper limit of normal) usually have acute pancreatitis, and additional serum enzyme testing is not helpful. Patients with smaller elevations of serum amylase often have conditions other than pancreatitis, and measurement of a serum enzyme more specific for the pancreas (pancreatitic isoamylase, lipase or trypsin) is frequently of diagnostic value in such patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1702756

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  39 in total

1.  Metastatic multiple myeloma with hyperamylasaemia and hyperlipasaemia.

Authors:  S Nair; P Sachan; H Hertan; C S Pitchumoni
Journal:  Postgrad Med J       Date:  1998-10       Impact factor: 2.401

2.  Tramadol poisoning with hyperamylasemia.

Authors:  Alaa El-Hussuna; Regnar Bøge Arnesen; Jacob Rosenberg
Journal:  BMJ Case Rep       Date:  2010-08-06

3.  Familial hyperamylasaemia.

Authors:  P M Cuckow; A Y Foo; A Jamal; M D Stringer
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

4.  Misdiagnosis of pancreatitis during valproate treatment in gastro-oesophageal reflux.

Authors:  R Riikonen
Journal:  Arch Dis Child       Date:  1996-10       Impact factor: 3.791

5.  Pancreas-specific plasma amylase for assessment and diagnosis of chronic pancreatitis: New insights on an old topic.

Authors:  Søren Schou Olesen; Henrik Krarup; Jakob Lykke Poulsen; Jeppe Hagstrup Christensen; Andrea Rhiannon Glynne Sheel; Robert Sutton; William Greenhalf; Christopher Halloran; Asbjørn Mohr Drewes
Journal:  United European Gastroenterol J       Date:  2019-04-16       Impact factor: 4.623

6.  Association of abdominal fat with serum amylase in an older cohort: The Baltimore Longitudinal Study of Aging.

Authors:  Jenny Pena Dias; Jennifer A Schrack; Michelle D Shardell; Josephine M Egan; Stephanie Studenski
Journal:  Diabetes Res Clin Pract       Date:  2016-04-26       Impact factor: 5.602

7.  Does acute ingestion of large amounts of alcohol cause pancreatic injury? A prospective study.

Authors:  J M Löhr; T Rabenstein; R Strauss; E G Hahn; M U Schneider
Journal:  Int J Pancreatol       Date:  1995-04

8.  Low serum pancreatic enzyme levels predict mortality and are associated with malnutrition-inflammation-atherosclerosis syndrome in patients with chronic kidney disease.

Authors:  Abdullah Ozkok; Omer Celal Elcioglu; Tahsin Cukadar; Ali Bakan; Gulsah Sasak; Kadir Gokhan Atilgan; Sabahat Alisir; Mehmet Kanbay; Adrian Covic; Ali Riza Odabas
Journal:  Int Urol Nephrol       Date:  2012-08-02       Impact factor: 2.370

Review 9.  Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis.

Authors:  Cheng-Jeng Tai; Chung-Huei Hsu; Shing-Chuan Shen; Woan-Ruoh Lee; Ming-Chung Jiang
Journal:  J Exp Clin Cancer Res       Date:  2010-08-11

10.  NSAIDs for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: ready for prime time?

Authors:  Mansour A Parsi
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.